Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer
Sponsor: National Cancer Centre, Singapore
Summary
The aim of the study is to improve the loco-regional control rate and overall survival of locally advanced head and neck squamous carcinoma (HNSCC). The investigators hypothesize that the addition of nimotuzumab (a recombinant humanized murine immune antibody that blocks both epidermal growth factor (EGF) and transforming growth factor (TGF)) to the current gold standard of concurrent chemoradiotherapy (CCRT) (7)(8), an adjuvant setting in patients after resection of their locally advanced HNSCC will confer therapeutic advantage.
Official title: Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell Cancer
Key Details
Gender
All
Age Range
21 Years - Any
Study Type
INTERVENTIONAL
Enrollment
422
Start Date
2009-08-13
Completion Date
2026-03-11
Last Updated
2026-11-20
Healthy Volunteers
No
Interventions
Nimotuzumab
Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
Placebo
Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
Locations (30)
Flinders Medical Centre
Bedford Park, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
National Institute of Oncology and Radiobiology
Vedado, Cuba
Alexandria University School of Medicine
Alexandria, Egypt
National Cancer Institute, Cairo University
Cairo, Egypt
Apollo Hospital Bangalore
Bangalore, India
Narayana Hrudayalaya Hospital (Mazumdar Shaw Cancer Institute)
Bangalore, India
Amrita Institute of Medical Sciences
Kerala, India
Tata Memorial Centre
Mumbai, India
Christian Medical College
Tamil Nadu, India
Regional Cancer Center Trivandrum, India
Trivandrum, India
Cipto Mangunkusumo General Hospital Indonesia
Jakarta, Indonesia
Pantai Medical Centre, Kuala Lumpur
Kuala Lumpur, Malaysia
Mahkota Medical Center
Malacca, Malaysia
University of Santo Tomas Hospital
Manila, Philippines
St. Luke's Medical Center
Quezon City, Philippines
King Fahad Medical City
Riyadh, Saudi Arabia
National Cancer Centre
Singapore, Singapore
The Oncology Centre
Durban, South Africa
GVI Oncology
Panorama, South Africa
National Cancer Center Korea
Gyeonggi-do, South Korea
INHA University Hospital
Incheon, South Korea
Samsung Medical Center
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
China Medical University Hospital
Taichung, Taiwan
Taipei Med Univ Hosp [TMUH]
Taipei, Taiwan
Taipei Veteran General Hospital
Taipei, Taiwan
National Cancer Institute Bangkok (+Chulabhorn for RT)
Bangkok, Thailand
Siriraj Hospital
Bangkok, Thailand
Chiang Mai Hospital
Chiang Mai, Thailand